GlassScriptPhysician profile
Robert Mason Daniels
NPI 1922069889
$11,804.02
in general payments reported to CMS, 2019-2025
55 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $2,077 · 2021: $1,764 · 2022: $1,087 · 2023: $1,258 · 2024: $1,898 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,415.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,392.54 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,306.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,078.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $999.16 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $859.85 | 2019-2025 | |
| Lilly USA, LLC | $689.08 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $541.30 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $476.06 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.94 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $374.92 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.88 | 2019-2024 | Jardiance, Tradjenta |
| Esperion Therapeutics, INC. | $300.49 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $248.02 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $188.61 | 2020-2025 | Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $177.55 | 2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.